Scientists test new drug cocktail in fight against tough pancreatic cancers
NCT ID NCT00878163
Summary
This early-stage study is testing the safety and best doses of a combination of two or three drugs (vismodegib, erlotinib, and sometimes gemcitabine) in people with advanced pancreatic cancer or other solid tumors that cannot be removed by surgery. The goal is to see if blocking different cancer growth pathways at once can kill more tumor cells. Researchers will closely monitor 55 participants for side effects and any early signs that the treatment is working.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC DUCTAL ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Mayo Clinic in Arizona
Scottsdale, Arizona, 85259, United States
-
Mayo Clinic in Florida
Jacksonville, Florida, 32224-9980, United States
-
Mayo Clinic in Rochester
Rochester, Minnesota, 55905, United States
-
Orlando Health Cancer Institute
Orlando, Florida, 32806, United States
Conditions
Explore the condition pages connected to this study.